MAP2K7 and sinus histiocytosis with massive lymphadenopathy: Recently, cobimetinib, an oral mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor was approved by the US Food and Drug Administration for histiocytic neoplasms, including RDD, due to excellent response rates in a phase 2 study.5